Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Authors:
- Luca Dalle CarbonareLuca Dalle Carbonare
- Mirko ZanattaMZMirko Zanatta
- Adriano GasparettoAGAdriano Gasparetto
- Maria Teresa ValentiMaria Teresa Valenti
Open Access
- 1 August 2010
- journal article
- review article
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 2, 121-137
Abstract
Bisphosphonates (BPs) are widely used in the treatment of postmenopausal osteoporosis and other metabolic bone diseases. They bind strongly to bone matrix and reduce bone loss through inhibition of osteoclast activity. They are classified as nitrogen- and non-nitrogen-containing bisphosphonates (NBPs and NNBPs, respectively). The former inhibit farnesyl diphosphate synthase while the latter induce the production of toxic analogs of adenosine triphosphate. These mechanisms of action are associated with different antifracture efficacy, and NBPs show the most powerful action. Moreover, recent evidence indicates that NBPs can also stimulate osteoblast activity and differentiation. Several randomized control trials have demonstrated that NBPs significantly improve bone mineral density, suppress bone turnover, and reduce the incidence of both vertebral and nonvertebral fragility fractures. Although they are generally considered safe, some side effects are reported (esophagitis, acute phase reaction, hypocalcemia, uveitis), and compliance with therapy is often inadequate. In particular, gastrointestinal discomfort is frequent with the older daily oral administrations and is responsible for a high proportion of discontinuation. The most recent weekly and monthly formulations, and in particular the yearly infusion of zoledronate, significantly improve persistence with treatment, and optimize clinical, densitometric, and antifracture outcomes.Keywords
This publication has 118 references indexed in Scilit:
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Alendronate and Atrial FibrillationNew England Journal of Medicine, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*International Journal Of Clinical Practice, 2006
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences, 2006
- Pharmacokinetics/Pharmacodynamics of BisphosphonatesClinical Pharmacokinetics, 2005
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without OsteoporosisJournal of Bone and Mineral Research, 2004
- Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human OsteoblastsBiochemical and Biophysical Research Communications, 2002
- Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2001